Effects of Standard Treatment of Acute Coronary Syndromes on Macrophage Activity as Measured by Serum Neopterin
Stopped early
Conditions studied: Acute Coronary Syndrome
In brief
This is a prospective observational study focused on monitoring the effects of various treatment options for acute coronary syndrome (ACS) patients by measuring serum neopterin levels. Serum neopterin is a marker for measuring macrophage activation. Prior studies have illustrated that there are elevated serum neopterin levels in ACS. Patients enrolled are those with ACS. Blood samples are drawn at presentation, and at 72 hours after admission, or at office visits and at 72 hours later. Neopterin levels are measured via a commercially available assay..
Key facts
- Study ID
- NCT00952055
- Run by
- Winthrop University Hospital
- People needed
- 152
- Starts
- 2003-07-01
- Expected to finish
- 2011-08-01
- Last updated by the study team
- 2015-01-16
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Chest pain and either ST segment elevation or depression > 0.1 mV in at least 2 contiguous electrocardiographic leads as well as elevation in troponin levels.
You may not qualify if…
- History of medical conditions known to alter neopterin concentrations in blood. The exclusion criteria includes:
- renal failure,
- history of HIV,
- transplant patients,
- active infections,
- history of autoimmune disease,
- malignancy,
- phenylketonuria,
- immune mediated liver disease, and
- patients taking immunomodulating therapy.
Where it is running
- Winthrop-University Hospital — Mineola, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.